An AU$3.2 million prize has been awarded to AIBN researchers and industry partner Vaxxas, to develop and distribute an easy to use, next-generation COVID-19 mRNA vaccine on the company’s needle-free patch.
The AIBN has the knowledge and infrastructure to ensure Australia can develop and deliver clinical-grade vaccines whenever, and wherever, they are needed.
Developing new, cost effective technologies to remediate and protect remote sites and waterways that have been contaminated ‘forever chemicals’ (PFAS).
AIBN researchers have created world leading ‘quantum dot’ technology for electricity conversion to deliver significant upgrades on traditional solar cell technology.
As the biggest supplier of mRNA vaccines and therapies for research in Australia, the AIBN’s BASE facility is well-positioned to lead the world in mRNA translation for biotechnology firms.
The AIBN BioBandage team are developing a hydrogel that harnesses replicated proteins from deadly snakes to stop uncontrolled bleeding from severe wounds.
AdvanCell is an Australian-based clinical-stage radiopharmaceutical company that is developing a range of novel therapies to boost cancer survival rates and improve patients’ quality of life.
Researchers at the AIBN are using synthetic biology to help the world’s biggest industries transition to net zero in a cutting-edge, Australian-first facility called the Biosustainability Hub.
